Fixed-Dose Trial in Early Parkinson's Disease (PD) (TEMPO-1)

Fixed-Dose Trial in Early Parkinson's Disease (PD) (TEMPO-1)
Not Recruiting
40-80 years
All
Phase 3
5 participants needed
1 Location

Brief description of study

The purpose of this study is to evaluate the clinical efficacy, safety and pharmacokinetics of 2 fixed doses of tavapadon and placebo in participants with early Parkinson's Disease

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Parkinson's Disease
  • Age: Between 40 Years - 80 Years
  • Gender: All

Male and female age 40-80 Diagnosis of Parkinson's Disease

Updated on 01 Aug 2024. Study ID: 843327

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center